

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

TEVA PHARMACEUTICALS)	
INTERNATIONAL GMBH,)	
CEPHALON, LLC, and EAGLE)	
PHARMACEUTICALS, INC.,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 23-490-JLH
)	C.A. No. 23-633-JLH
BENDARX CORP.,)	
)	
Defendant.)	
_____)	

STIPULATION AND ~~PROPOSED~~ ORDER

Plaintiffs Teva Pharmaceuticals International GmbH, Cephalon, LLC, and Eagle Pharmaceuticals, Inc. (collectively, “Plaintiffs”) and Defendant BendaRx Corp. (“BendaRx”) by their undersigned counsel, stipulate and agree as follows:

WHEREAS, after receiving Notice of Paragraph IV Certifications, Plaintiffs filed Complaints (C.A. No. 23-490-JLH, D.I. 8; C.A. No. 23-633-JLH, D.I. 1) against BendaRx in the above-captioned actions, asserting infringement of U.S. Patent Nos. 8,076,366 (the “#366 Patent”) and 9,572,887 (the “#887 Patent”), among others;

WHEREAS, BendaRx represents that the New Drug Application (“NDA”) No. 215291 produced in these actions accurately describes the drug product sought to be marketed upon approval of that application;

NOW THEREFORE, Plaintiffs and BendaRx hereby stipulate and agree, subject to the approval of the Court, as follows:

1. To conserve judicial resources and to avoid the time and expense of further litigation related to the #366 and #887 Patents, Plaintiffs stipulate to dismissal of Counts XVII, XVIII, XIX, and XX of Plaintiffs’ Complaints (C.A. No. 23-490-JLH, D.I. 8; C.A. No. 23-633-JLH, D.I. 1) asserting infringement of the #366 and #887 patents in connection with the products that are the subject of NDA No. 215291 (the “BendaRx NDA Products” as defined in paragraph 2, and such products only) with prejudice.

2. For clarity, the BendaRx NDA Products mean the products as described in NDA No. 215291 as produced by BendaRx in this litigation on August 2, 2023, including any amendments and supplements thereto but excluding amendments and supplements thereto that (1) change the dosage form (*i.e.*, the physical form in which a drug is produced and dispensed, such as a tablet, a capsule, a lyophilized powder, or a liquid injectable) of those products, (2) materially alter the freeze drying process used during preparation of the BendaRx NDA Products, and/or (3) otherwise alter the basis for NDA No. 215291’s

Paragraph IV certifications or assertions of non-infringement of the #366 and #887 Patents.

3. The parties agree that this stipulation does not require the parties to submit further briefing regarding BendaRx's motions to dismiss (C.A. No. 23-490-JLH, D.I. 12; C.A. No. 23-633-JLH, D.I. 10).

SHAW KELLER LLP

/s/ Emily S. DiBenedetto

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
Nathan R. Hoeschen (No. 6232)
Emily S. DiBenedetto (No. 6779)
I.M. Pei Building
1105 North Market Street, 12th Floor
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
nhoeschen@shawkeller.com
edibenedetto@shawkeller.com

*Attorneys for Teva Pharmaceuticals
International GmbH and
Cephalon, LLC*

OF COUNSEL:

David I. Berl
Adam D. Harber
Elise M. Baumgarten
Ben Picozzi
WILLIAMS & CONNOLLY LLP
680 Maine Avenue SW
Washington, DC 20024
(202) 434-5000

*Attorneys for Teva Pharmaceuticals
International GmbH and
Cephalon, LLC*

RICHARDS, LAYTON & FINGER, P.A

/s/ Travis S. Hunter

Travis S. Hunter (No. 5350)
Nathalie A. Freeman (No. 7053)
One Rodney Square
920 North King Street
Wilmington, DE 19801
(302) 651-7700
hunter@rlf.com
freeman@rlf.com

Attorneys for Defendant BendaRx Corp.

OF COUNSEL:

Anne Li
CROWELL & MORING LLP
590 Madison Avenue
20th Floor
New York, NY 10022

Mark Remus
CROWELL & MORING LLP
455 N. Cityfront Plaza Drive
NBC Tower, Suite 3600
Chicago, IL 60611

Shannon Lentz
Kassidy Schmitz
CROWELL & MORING LLP
1001 Pennsylvania Avenue NW
Washington, DC 20004

Attorneys for Defendant BendaRx Corp.

MCCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (No. 4758)
Alexandra M. Joyce (No. 6423)
Renaissance Centre
405 North King Street, 8th Floor
Wilmington, DE 19801
(302) 984-6300
dsilver@mccarter.com
ajoyce@mccarter.com

*Attorneys for Plaintiff Eagle
Pharmaceuticals, Inc.*

OF COUNSEL:


Daniel G. Brown
LATHAM & WATKINS LLP
555 Eleventh Street, NW, Suite 1000
Washington, DC 20004

Kenneth G. Schuler
Marc N. Zubick
Alex M. Grabowski
LATHAM & WATKINS LLP
330 North Wabash Avenue, Suite 2800
Chicago, IL 60611
(312) 876-7700

*Attorneys for Plaintiff Eagle
Pharmaceuticals, Inc.*

Dated: January 19, 2024

IT IS SO ORDERED this 22nd day of January, 2024.



The Honorable Jennifer L. Hall
United States District Judge